Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues.

Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues.

Many mechanisms have been proposed to explain why immune responses against human tumor antigens are generally ineffective. For example, tumor cells have been shown to develop active immune evasion mechanisms. Another possibility is that tumor antigens are unable to optimally stimulate tumor-specific...

Bibliografske podrobnosti
Main Authors:	Valmori, D, Fonteneau, J, Valitutti, S, Gervois, N, Dunbar, R, Liénard, D, Rimoldi, D, Cerundolo, V, Jotereau, F, Cerottini, J, Speiser, D, Romero, P
Format:	Journal article
Jezik:	English
Izdano:	1999

Podobne knjige/članki

Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376.
od: Valmori, D, et al.
Izdano: (1999)

Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
od: Valmori, D, et al.
Izdano: (2000)

An antigen-targeted approach to adoptive transfer therapy of cancer.
od: Valmori, D, et al.
Izdano: (1999)

Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes.
od: Romero, P, et al.
Izdano: (1998)

Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3.
od: Valmori, D, et al.
Izdano: (1999)

High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.
od: Pittet, M, et al.
Izdano: (1999)

In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes.
od: Speiser, D, et al.
Izdano: (1999)

CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients.
od: Speiser, D, et al.
Izdano: (1999)

Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients.
od: Valmori, D, et al.
Izdano: (2000)

Immune monitoring in cancer immunotherapy.
od: Romero, P, et al.
Izdano: (2000)

Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
od: Chen, J, et al.
Izdano: (2000)

The efficiency of antigen recognition by CD8+ CTL clones is determined by the frequency of serial TCR engagement.
od: Hudrisier, D, et al.
Izdano: (1998)

Tumor cell recognition efficiency by T cells.
od: Daniel E Speiser, et al.
Izdano: (2005-03-01)

Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas.
od: Juliette Desfrançois, et al.
Izdano: (2010-01-01)

Quantitating T cell cross-reactivity for unrelated peptide antigens.
od: Ishizuka, J, et al.
Izdano: (2009)

1379 Novel backbone-modified analogues of antigenic peptides improve immunogenic capabilities of anti-tumor peptide vaccines
od: Douglas McNeel, et al.
Izdano: (2023-11-01)

Antigen presentation. Naturally processed peptides.
od: Elliott, T, et al.
Izdano: (1990)

The efficiency of antigen recognition by CTL is determined by the frequency of serial TCR engagement.
od: Hudrisier, D, et al.
Izdano: (1998)

Antigenic reactivity of peptides derived from wheat gluten with sera from patients with coeliac disease.
od: Rawcliffe, P, et al.
Izdano: (1985)

Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.
od: Youde, S, et al.
Izdano: (2000)

Effects of epitope modification on T cell receptor-ligand binding and antigen recognition by seven H-2Kd-restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative.
od: Kessler, B, et al.
Izdano: (1997)

Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time.
od: Aleksic, M, et al.
Izdano: (2010)

Using modified antigenic sequences to develop cancer vaccines: are we losing the focus?
od: Danila Valmori, et al.
Izdano: (2004-11-01)

Reactivity of sulfonylbutadienes. Synthesis of Ginsenol analogues
od: David Diez, et al.
Izdano: (2010-10-01)

A tumor-binding antibody with cross-reactivity to viral antigens
od: Michael J. Campa, et al.
Izdano: (2025-02-01)

Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I.
od: Griffiths, E, et al.
Izdano: (1998)

High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence
od: Laura Carretero-Iglesia, et al.
Izdano: (2020-01-01)

Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells.
od: Larsson, M, et al.
Izdano: (2000)

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.
od: André, P, et al.
Izdano: (1998)

Synthesis and reactivity of novel gamma-phosphate modified ATP analogues.
od: Lee, SE, et al.
Izdano: (2009)

Synthesis and reactivity of novel γ-phosphate modified ATP analogues
od: Lee, SE, et al.
Izdano: (2009)

Synthesis of a novel analogue of peptide ProGlyPro
od: A. V. Baranov, et al.
Izdano: (2006-12-01)

Identifying individual T cell receptors of optimal avidity for tumor antigens
od: Michaël eHebeisen, et al.
Izdano: (2015-11-01)

IMMUNOMODULATORY ACTIVITY OF ANTIMICROBIAL PEPTIDE INDOLICIDIN AND ITS STRUCTURAL ANALOGUES
od: A. Yu. Artamonov, et al.
Izdano: (2014-07-01)

363 Identification of dark antigen® reactive T cell receptors from tumor-infiltrating lymphocytes
od: Özcan Met, et al.
Izdano: (2023-11-01)

Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production.
od: Kessler, B, et al.
Izdano: (1998)

Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency
od: Lahman, MC, et al.
Izdano: (2022)

Tumor-Specific CircRNA-Derived Antigen Peptide Identification for Hepatobiliary Tumors
od: Wenwen Wang, et al.
Izdano: (2023-03-01)

Exogenous peptides delivered by ricin require processing by signal peptidase for transporter associated with antigen processing-independent MHC class I-restricted presentation.
od: Smith, D, et al.
Izdano: (2002)

Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy.
od: Speiser, D, et al.
Izdano: (1997)